Neutralny
Pfizer's stock remains steady at $24.94 amid mixed market signals.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Over the past 24 hours, Pfizer's stock price has remained relatively unchanged, closing at $24.94 on July 21, 2026. This stability comes despite recent developments, including a 1.3% increase in share price on July 16, 2026, following FDA approval for a new bladder cancer regimen. However, the stock has also faced challenges, such as a 2.7% decline on June 24, 2026, due to a Phase 3 lung cancer drug candidate failing to meet survival expectations.
Kluczowe punkty
- FDA approval for new bladder cancer regimen boosts investor confidence.
- Phase 3 lung cancer drug trial misses survival goal, raising pipeline concerns.
- Stock price remains steady at $24.94, reflecting market indecision.
Źródła
- Pfizer (NYSE:PFE) Stock Price Up 1.3% - Here's WhyMarketBeat · July 16, 2026
- Pfizer (NYSE:PFE) Shares Down 2.7% - What's Next?MarketBeat · June 24, 2026
- Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals BuildSimply Wall St News · July 21, 2026
- Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceNasdaq · February 3, 2026
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
